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Abstract
Purpose of review—Antimicrobials are a leading cause of severe T-cell-mediated adverse drug 
reactions (ADRs). The purpose of this review is to address the current understanding of 
antimicrobial cross-reactivity and the ready availability of and evidence for in vitro, in vivo and ex 
vivo diagnostics for T-cell-mediated ADRs.
Recent findings—Recent literature has evaluated the efficacy of traditional antibiotic allergy 
management including patch testing, skin prick testing, intradermal testing and oral challenge. 
While patch and intradermal testing are specific for the diagnosis of immune-mediated (IM) 
ADRs, they suffer from drug-specific limitations in sensitivity. The use of ex vivo diagnostics, 
especially ELISpot has been highlighted as a promising new approach to assigning causality. 
Knowledge of true rates of antimicrobial cross-reactivity aids empirical antibiotic choice in the 
setting of previous IM-ADRs.
Summary—In an era of increasing antimicrobial resistance and use of broad-spectrum 
antimicrobial therapy, ensuring patients are assigned the correct “allergy label” is essential. Re-
exposure to implicated antimicrobials, especially in the setting of severe adverse cutaneous 
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reaction is associated with significant morbidity and mortality. The process through which an 
antibiotic label gets assigned, acted on and maintained is still imprecise. Predicting T-cell-
mediated ADRs via personalised approaches, including HLA-typing may pave future pathways to 
safer antimicrobial prescribing guidelines.
Keywords
ELISpot; antibiotic allergy; severe cutaneous adverse reactions; patch testing; hypersensitivity; 
lymphocyte transformation test
Introduction
T-cell-mediated drug hypersensitivities are a group of immune-mediated (IM) adverse drug 
reactions (ADRs) of varying phenotype and severity. Descriptions of antimicrobial 
associated T-cell-mediated ADRs date back to the use of the first sulfa antimicrobials [1] 
and then almost a decade later to early preparations of penicillins [2,3]. These IM-ADRs 
result in antimicrobial allergy “labels” that impact patient outcomes and antimicrobial usage 
[4–6]. For the diagnosis of antimicrobial allergy, the use of skin prick and intradermal 
testing (SPT/IDT) remain the mainstay of first-stage diagnosis for immediate reactions 
suspected to be IgE-mediated. This should be followed by an ingestion challenge which, in 
combination with SPT/IDT, is still considered to be the gold standard [7]. However, in the 
setting of serious T-cell-mediated ADRs, both patch testing, a more established test for the 
diagnosis of delayed reactions, and SPT/IDT lack the 100% negative predictive value 
necessary to re-challenge patients to drugs either orally or systemically following negative 
testing [8]. In this review, we will address the current understanding of antimicrobial cross-
reactivity and the ready availability of and evidence for IM-ADR in vitro, in vivo and ex 
vivo diagnostics.
The epidemiology of serious T-cell-mediated reactions varies according to the region studied 
and is driven by genetic predisposition to these reactions. In general, given the high 
prevalence of antibiotic use, 50% or more of severe cutaneous adverse reactions (SCAR) 
globally are associated with antimicrobials, commonly penicillins, glycopeptides and 
sulphonamide antibiotics and antiretrovirals [5,9,10]. The most serious of these reactions 
include Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction 
with eosinophilia and systemic symptoms (DRESS) and acute generalised exanthematous 
pustolosis (AGEP). Additionally, abacavir, a guanosine analogue nucleoside reverse 
transcriptase inhibitor (NRTI), is associated with a severe HLA-B*57:01-restricted, CD8+ T-
cell-mediated hypersensitivity reaction (AHS) which is characterized clinically by fever, 
malaise, gastrointestinal symptoms and late onset of rash (70%) a median of 8 days after 
initiation of dosing. In the setting of multiple implicated antimicrobials, the cause of SCAR 
and other IM-ADRs is often unclear despite application of published causality assessments 
[11,12].
Effector immunology of T-cell-mediated ADRs
IM-ADRs can be classified by the revised Gell and Coombs classification (Table 1)[13]. 
This review focuses on Type IV, T-cell-dependent IM-ADRs. The pathogenesis of T-cell-
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mediated immune responses has been long debated, yet the presence of allergen-specific T 
lymphocytes is an observation in most drug-allergy reactions. White et al. reviewed the 
current mechanistic hypotheses of T-cell-dependent IM-ADRs namely (i) pharmacological 
interaction of drugs with immune receptors (the p-i concept), (ii) the hapten/pro-hapten 
model and (iii) the altered peptide repertoire model (Figure 1)[4]. The cellular and cytokine 
response within IM-ADRs vary (Table 1).
Many of the SCAR reactions are known to rely on drug specific T-cell responses that can 
persist in the circulation for >20 years after drug exposure [60]. Blistering and severe IM-
ADRs (SJS/TEN or AHS) are thought to correlate with CD8+ T-cell infiltration, while 
simple exanthema and DRESS are largely associated with CD4+ T cells or mixtures of 
CD4+ and CD8+ T cells [61,62]. In general, cytokines upregulated in IM-ADRs are IL-2, 
IL-5, IL-13 and IFN-y [63]. The key immune mediators differ slightly for each IM-ADR 
phenotype, summarised in Table 1. An understanding of immune mediators is vital for future 
works measuring cytokines in ex vivo T-cell diagnostics.
Historical approaches to T-cell-mediated hypersensitivities
Testing for IM-ADRs remains problematic due to both lack of widespread availability and 
low sensitivity of conventional methods. Many patients with non-specific rashes or those 
that occur during the course of an acute infection will not demonstrate reproducible 
symptoms on future rechallenge. Caubet et al. demonstrated that only 6.8% of patients with 
a history of antibiotic associated “rash” had a reproducible phenotype on oral challenge. In 
recent studies, IDT has been suggested to be more sensitive than patch testing (PT) for T-
cell-mediated ADRs [64]. However, in the setting of serious T-cell-mediated ADRs, PT is 
still considered “safer” than delayed-SPT/IDT [65,66]. The details of PT and IDT for T-cell-
mediated ADRs are described below and a summary of T-cell-mediated ADRs is provided in 
Table 2.
Patch testing (PT)
The specificity of PT for SCAR has been high in settings where drug concentrations have 
been validated against negative controls. The sensitivity of PT varies, however, and is 
highest for DRESS (32–80%) [112,113] and AGEP (58–64%) [112,114], and lowest for 
SJS/TEN (9–24%) [112,114] and MPE (10–40%) [65,113]. Patch testing lacks an 
appropriate positive control and results may be difficult to interpret in patients who are on 
immunosuppressants that impact T-cell-mediated immunity. For antibiotics, PT to the upper 
back is generally recommended 6 weeks – 6 months post skin healing [115]. In a multicentre 
study of PT in SCAR, Barbaud et al. demonstrated that PTs were most frequently positive 
for beta-lactams (primarily amoxicillin) and pristinamycin [112]. Buonomo et al. 
demonstrated PT’s utility in IM-ADRs, predominately cephalosporin-associated MPE, in a 
retrospective cohort [116]. Barbaud et al. utilized PT in 29 cases of pristinamycin-associated 
IM-ADRs, with a higher that expected sensitivity noted (69%) [66]. In 27 patients with oral 
challenge confirmed FDE to TMP-SMX, a 93% sensitivity for PT was demonstrated [117]. 
However, in a recent study by Andrade et al. 0% (0/15) of FDE were positive on PT [118]. 
The utility of PT in IM-ADRs caused by quinolones and trimethoprim-sulfamethoxazole 
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(TMP-SMX) is notoriously poor [112,119,120]. PT has been demonstrated to be effective in 
a small number of antibiotic-associated SJS/TEN [114,121–123], AGEP 
[70,112,120,124,125], FDE [126–128], DRESS [112,129], MPE [130] and EM [131] case 
series. To date, success with PT in cases of suspected antiretroviral hypersensitivity has been 
limited to abacavir. PT for abacavir showed 100% specificity and 87% diagnostic sensitivity 
when used as an adjunctive test to define true AHS [8,132].
Summary & Recommendations
i. A positive PT has high specificity for a specific antibiotic-associated IM-
ADRs and appears most useful for DRESS >AGEP and of lessor utility for 
FDE, MPE and SJS/TEN.
ii. A negative PT does not exclude a drug-specific IM-ADR and should never 
be used as the sole basis for rechallenge of the implicated antibiotic(s).
Delayed intradermal testing (Delayed-IDT)
The use of delayed-IDT (0.02–0.05 mLs of highest non-irritating concentration of 
antimicrobial applied to volar forearm skin, then read at 48–72 hours [133]) is recommended 
in the investigation of T-cell-mediated ADRs [134,135]. Similar to patch testing, delayed-
IDT is limited by the significantly less than 100% sensitivity and lack of a suitable positive 
control [136]. Recommendations for IDT vary regionally and there is a lack of evidence-
based volumes and reagents (beta-lactam versus non-beta-lactam) [121,133–135]. IDT has 
predominately been utilized for beta-lactam antimicrobials, especially penicillins > 
cephalosporins, in patients with a history of non-SJS/TEN T-cell-mediated ADR 
[122,123,137]. A positive result involves dermal induration/erythema at injection site, which 
will significantly exceed 5 mm from baseline, 24–72 hours post-testing. Although extension 
of the local dermal response at the skin testing site is uncommon, IDT is generally not 
recommended for the assessment of SJS/TEN [123,138], due to risk of systemic events. 
Adverse reactions following delayed IDT for non-SJS/TEN ADRs are rarely reported [139–
141], primarily occur in the setting of immediate testing [142–144] and are often related to 
errors in concentrations and/or volumes used.
Alternative guidelines do not specify the same ‘contraindications’ to IDT, however suggest 
performing IDT only after a negative PT [145]. Whilst it appears PT is preferred over IDT 
for FDE [118], the sensitivity of IDT for other T-cell-mediated ADRs appears higher than 
that observed with PT [64,130,141,146,147]. In a study of patients with suspected reactions 
to beta-lactams (n = 235 MPE), 7% (18/235) had a positive delayed-IDT, while 8.5% 
(20/235) with negative IDT demonstrated a positive result with OC [147]. IDT has also been 
used less frequently for other antimicrobials associated with IM-ADRs, such as 
metronidazole [148]. Limitations include (i) only antimicrobials in a commercially available 
and sterile injectable form can be utilized, (ii) short-lived local histamine release (e.g. 
ciprofloxacin and vancomycin) and irritation (e.g. flucloxacillin) of some products and (iii) 
overall low NPV. The sensitivity of delayed-IDT from a mixture of small studies has been 
reported as 6.6–36.3% for MPE (higher with penicillins > cephalosporins) [149–151] and 
64%–100% for DRESS [113,137].
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i. Delayed-IDT can be employed as a first line investigation for non-
SJS/TEN IM-ADRs, although the highest non-irritating concentrations for 
DELAYED testing have not been validated for most drugs.
ii. A positive delayed-IDT result is highly suggestive of an IM-ADR, but a 
negative delayed-IDT does not exclude an IM-ADR and should never be 
used as the sole basis for rechallenge.
Direct oral challenge
Since first-stage tests such as PT and IDT do not have 100% negative predictive values, oral 
challenge is contraindicated in certain SCAR (e.g. SJS/TEN/DRESS) [8,152] and AHS. Oral 
challenge is required to confirm IM-ADRs following negative delayed-IDT or PT in the 
remaining phenotypes [150,153]. For the investigation of delayed reactions, a prolonged oral 
challenge (5–7 versus 3 days) increases sensitivity [150,154]. Due to the low rate of 
positives obtained from isolated delayed-IDT or PT [153,155–157], and high rate of Type A 
ADRs clouding “labels” [6], a move toward direct oral challenge has been proposed, 
especially for ‘low-risk’ phenotypes [6,158]. This is particularly true in children where viral 
infections or drug-infection interactions are prevalent. Direct oral rechallenge in a cohort of 
patients with a history of MPE demonstrated only a 6.9% adverse event rate (compared with 
3.5% prior) [159]. A direct 5-day oral rechallenge in 119 pediatric patients with mild 
antibiotic-associated MPE elicited a 5.4% positive response rate, none of which were serious 
[80]. The safety of oral rechallenge for antiretroviral IM-ADRs has not been established, but 
guidelines advise that patients with mild to moderate rash without constitutional symptoms 
can continue antiretrovirals with close clinical monitoring. In these cases, symptoms should 
be managed with anti-histamines and topical corticosteroids. Physicians commonly “treat 
through” mild ADRs to non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as 
nevirapine or efavirenz, hepatitis C drugs such as telaprevir and antibiotics such as beta-
lactams and sulfa antimicrobials [160,161]. Desensitization protocols exist for 
hypersensitivity reactions to the antiretrovirals tipranavir [162], amprenavir [163], darunavir 
[164], efavirenz [165] and have been tried with nevirapine [166].
Recommendations
i. Direct oral challenge for 5–7 days should be employed after a negative PT 
or delayed-IDT in the setting of mild to moderate antibiotic skin rashes 
without evidence of fever, mucosal involvement, malaise or internal organ 
involvement.
ii. Oral challenge with a suspected drug should never be employed in the 
setting of SJS/TEN or DRESS.
iii. Ideally, an observed oral or ingestion challenge in the setting of required 
antibiotic therapy should be employed following negative IDT/PT and 
knowledge of antibiotic cross-reactivity (Box 1).
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iv. In acute settings, of mild to moderate rash without fever, mucosal or 
internal organ involvement, antimicrobials can be continued with close 
monitoring.
Box 1
Heading: Empirical antimicrobial therapy recommendations in the setting 
of T-cell-mediated ADR (non-SCAR) where in vivo and ex vivo testing is not 
available



































SCAR, severe cutaneous adverse reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis; drug 
reaction with eosinophilia and systemic symptoms; acute generalised exanthematous pustolosis.
ADR, adverse drug reaction.
a
Avoid if amoxicillin/ampicillin delayed IM-ADR due to shared/similar R1 side chain
b
If cefazolin is the implicated antimicrobial, this is generally an isolated reaction due to the absence of shared 
side chains and therefore other beta-lactams could be employed for non-SCAR phenotypes.
c
If cephalexin allergy then avoid amoxicillin/ampicillin due to shared/similar R1 side chain
d
Avoid if cephalexin allergy due to shared/similar R1 side chain
e
Avoid if cefuroxime allergy due to shared/similar R1 side chain
f
Avoid if cefaclor allergy, due to shared/similar R1 side chain
g
Avoid if ceftriaxone allergy due to shared/similar R1 side chain.
h
Avoid if cefoxitin allergy due to shared/similar R1 side chain.
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Avoid if ceftazadime allergy due to shared/similar R1 side chain
j
Avoid if cefepime allergy due to shared/similar R1 side chain
k
Avoid if aztreonam allergy due to shared/similar R1 side chain
T-Cell Diagnostics
Lymphocyte transformation test
Ex vivo investigations have been explored for T-cell-mediated ADRs, including the 
lymphocyte transformation test (LTT). LTT has a reported sensitivity of 27–70% and 
specificity of 72.7–100%, however remains hindered by testing time, requirement for 
radioactive materials and potential dependence on B-cell proliferation [8,175–177]. LTT has 
been used for causality assessments in ceftriaxone, ampicillin/sulbactam and metronidazole-
associated linear IgA disease, ceftriaxone-associated MPE, penicillin/amoxicillin-induced 
MPE and ceftazidine-induced DRESS [178–181]. In a small study of amoxicillin-induced 
IM-ADR, correlation between positive in vivo IDT and LTT was not demonstrated [182]. 
LTT has also been used in a small number of other case reports/series for IM-ADRs 
secondary to anti-tuberculosis therapies [129], aminopenicillins [122,123,177], 
cephalosporins [183] and anti-staphylococcal penicillins [137].
Recommendation
i. Antibiotic LTT is an unvalidated test that has been associated with both 
false positive and false negative results and currently remains a research 
tool used in specialized centres for the investigation of T-cell-mediated 
ADRs.
Enzyme-Linked ImmunoSpot (ELISpot) Assay
ELISpot is an ex vivo technique used to analyse low-frequency antigen-specific, cytokine-
producing (e.g. IFN-γ) cells in peripheral blood following exposure to pharmacological drug 
concentrations [8]. ELISpot can be employed for a range of cytokine responses depending 
on the underlying drug hypersensitivity immunopathogenesis. For example, AGEP can have 
high IL-13 and IFN-γ, FDE raises IL-10, while DRESS can have high IL-5 or IFN-γ 
[60,184]. ELISpots measuring granzyme have also been employed [175]. ELISpot studies 
have demonstrated that 1:150 to 1:5000 T cells remain ‘reactive’ in patients post ADR for up 
to 12–20 years [60,185]. ELISpot has also been shown to have better sensitivity than LTT in 
detecting drug-specific T-cell responses [185,186]. Nonetheless, ELISpot has only been 
employed in research settings for the investigation of antimicrobial allergy. Estimations of 
sensitivity and specificity are flawed due to the absence of a reference gold standard. 
However, increasing the drug concentration used to stimulate the patients’ cells and 
increasing incubation periods (48 hours vs. overnight) have been shown to increase assay 
sensitivity without decreasing specificity. An examination of ELISpot use in antimicrobial T-
cell-mediated ADRs is outlined below:
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ELISpot & Antiviral IM-ADRs
ELISpot is described in studies examining antiretroviral hypersensitivity reactions, notably 
abacavir and nevirapine. ELISpot has been used to detect abacavir hypersensitivity in 
patients that are HLA-B*57:01 negative [187]. IFN-γ ELISpot has also been used to 
demonstrate that abacavir unexposed HLA-B*57:01 positive patients have a ‘resting’ 
abacavir reactive CD8+ T-cell population [188]. In nevirapine hypersensitivity reactions, 
IFN-γ ELISpot has been utilised to demonstrate that specific combinations of CD4 class II-
restricted and CD8 class I-restricted T cells contribute to the hypersensitivity 
immunopathogenesis [189].
ELISpot & Antibiotic IM-ADRs
Penicilins
Earlier studies demonstrate that ELISpot IFN-γ testing was positive in patients with a 
history of amoxicillin IM-ADRs [185,190]. No positive ELISpot results were identified in 
control patients or those with a history of IgE-mediated disease, highlighting the specificity 
of the test. The intensity of response was, however, proportional to time after diagnosis. The 
overall sensitivity and specificity was 91% and 95% respectively. Khalil et al. demonstrated 
a sensitivity and specificity of 80% and 100% respectively for ELISpot measuring IL-2, IL-5 
and IFN-y in patients with amoxicillin IM-ADR. Rozieres et al. demonstrated ex vivo 
effectiveness for other beta-lactams, including ticarcillin [185,191]. ELISpot has also been 
used in models using antigen-specific T-cell clones to confirm patients with a history to 
piperacillin hypersensitivity [192].
Cephalosporins
Tanvarasethee et al. examined the use of ELISpot to diagnose cephalosporin-induced MPE 
and compare against SPT, delayed-IDT and PT [193]. From the 25 patients, 40% had a 
positive IFN-γ and IL-5 response compared with 8% who had a positive delayed-IDT or PT 
(p= 0.008). There was a higher probability of positive ELISpot if performed within 2 years 
of reaction (p=0.046) [193].
Other antimicrobials
The use of ELISpot for quinolones, glycopeptides, trimethoprim-sulfamethoxazole and other 
commonly used antibacterial therapy is absent. Aminoglycosides are an infrequent cause of 
SCAR, yet a case of amikacin-induced DRESS was confirmed on patch testing and ELISpot 
[194]. A case of sulfasalazine hypersensitivity syndrome was also confirmed with ELISpot 
[195]. The use in other antimicrobials is also ill-defined. Further research is required to 
evaluate this testing in a range of antimicrobial therapies.
Recommendation
i. ELISpot remains a test available only in specialized centres for the 
investigation of T-cell-mediated ADRs.
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Predicting T-cell Responses – HLA typing
Recently, an increasing number of antimicrobial IM-ADRs have been associated with 
various HLA alleles (Table 3). In general, due to varying HLA allele frequencies, different 
ethnic populations have different genetic associations. To date, the best characterized 
antimicrobial-induced, HLA-associated IM-ADRs that appear to generalize across 
populations include AHS and nevirapine SCAR. The association between AHS and HLA-
B*57:01 resulted in the implementation of a routine screening test that is widely employed 
in the developed world before abacavir treatment. Before widespread acceptance, the HLA-
B*57:01 genetic association with abacavir was established in a large population with a 
diverse genetic background. This screening test has a positive predictive value (PPV) of 55% 
and a negative predictive value (NPV) of 100%, which is crucial for drug safety [218–220]. 
Less than 100% NPVs and very low PPVs of other antimicrobial drug hypersensitivity HLA 
associations have limited their translation into routine clinical practice as screening tests. For 
example, although only 13 individuals would need to be screened for HLA-B*57:01 to 
prevent a single case of AHS, over 14,000 individuals would have to be tested for this same 
allele to prevent a single case of flucloxacillin-associated hepatitis.
The story of nevirapine-induced IM-ADRs is quite complex. Nevirapine-induced IM-ADRs 
have been associated with different HLA alleles across different ethnic populations. These 
HLA associations appear to be phenotype specific and involve both Class I and Class II 
HLA alleles. An association between nevirapine-induced hepatitis and HLA-DRB1*01:01 
was first reported in a Western Australian population [217] and has since been reported in 
other Caucasian populations [216]. The closely related allele HLA-DRB1*01:02 was 
associated with nevirapine-induced hepatitis in a South African cohort [196]. Nevirapine 
DRESS has been associated with the HLA-Cw*8 or Cw*8-B*14 haplotype in Japanese and 
Italian populations and also with HLA-Cw*4 and HLA–DRB1*15 in Han Chinese, HLA-
B*35:05 in Asians and HLA-B*35:01 and HLA-B*15/DRB1*15 in an Australian cohort 
[189,212–215]. Many of these alleles including HLA-DRB*01, HLA-Cw*04 and HLA-
B*35:05 are also associated with nevirapine-induced rash [209–211,215,216].
Other HLA associations have been described for IM-ADRs to efavirenz, dapsone, 
flucloxacillin, amoxicillin-clavulanante, sulfamethoxazole, aminopenicillins, 
sulphonamides, isoniazid and levamisole (Table 3).
Many of these antimicrobials such as flucoxacillin and amoxicillin-clavulanate are 
specifically associated with drug-induced liver injury (DILI), which can be associated with 
fulminant hepatic failure [220]. Although few HLA screening tests have advanced to the 
level of routine clinical practice, HLA associations have significantly advanced our 
understanding of the immunopathogenesis of IM-ADRs.
Recommendation
i. Level IA evidence exists to support screening for HLA-B*57:01 prior to 
initiation of abacavir therapy. This screening test has a 100% negative 
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predictive value and is widely recommended as part of guideline-based 
practice.
Cross Reactivity in T-Cell-Mediated Reactions
In settings where in vivo and ex vivo diagnostics are unavailable, understanding cross-
reactivity based on shared chemical structure amongst antimicrobials is essential (Box 1). 
Most of the rates of cross-reactivity for delayed IM-ADRs are extrapolated from data that 
exists for cross-reactivity in the setting of immediate hypersensitivities. Earlier reports of 
high rates of penicillin/cephalosporin cross-reactivity were confounded by penicillin 
contamination of cephalosporin manufacturing [2,3,222]. Current literature supports that 
most cross-reactivity that occurs in the beta-lactam class occurs on the basis of shared R1 
and/or R2 side-chains [85,149,150). Recent reports suggest patients with a history of 
delayed hypersensitivity to aminopenicillins most commonly cross react with 
aminocephalosporins sharing an R1 group such as cephalexin, cefaclor and cephadroxil and 
generally tolerate all other cephalosporins [223,224]. Challenging patients with a penicillin/
amoxicillin allergy history with a cephalosporin not sharing the same side chain (e.g. 
cefuroxime or ceftriaxone) proved successful in a study of 41 patients by Novalbas et al. 
[225]. The rate of cross-reactivity between penicillin and 3rd generation cephalosporins now 
approaches 1%, a far cry from the 10–25% initially quoted in very early studies [226] 
Romano et al. demonstrated that patients with cephalosporin immediate hypersensitivity can 
still be safely treated with compounds that have side-chain determinants different from those 
of the responsible cephalosporin [169].
Cross-reactivity between carbapenems has been infrequently reported [227]; a shared T-cell 
epitope remains unknown [227]. Cross-reactivity between macrolides also appears rare, with 
infrequent reports of immediate cross-reactivity noted particularly between those with 14-
membered ring such as erythromycin, clarithromycin and roxithromycin and the 15-
membered azalide, azithromycin [228]. T-cell-mediated cross-reactivity between 
tetracyclines [229], in particular doxycycline and minocycline has been reported [229]. 
Cross-reactivity [230] and tolerance [231] have been reported for aminoglycoside antibiotics 
in which ADRs are more common for topical than systemic agents due to contact 
sensitization [194,232]. For nitroimidazoles (e.g. metronidazole, tindazole) T-cell-mediated 
ADRs have been reported, with cross-reactivity noted [94–96,233].
Delayed IM-ADRs are less frequent than immediate ADRs in regards to quinolones [234], 
with cross-reactivity more commonly occurring between 1st and 2nd generation quinolones 
than 3rd and 4th generation [234–237]. Glycopeptide (vancomycin and teicoplanin) cross-
reactivity is also reported [238–240], however remains controversial, with many reports 
extrapolated from reoccurrence of haematological disturbances. Patients with isolated 
vancomycin hypersensitivity have also been known to tolerate teicoplanin [97,238,241–243].
An estimated 3–6% of the population are considered “allergic” to sulphonamides, with 
trimethoprim-sulfamethoxazole (TMP/SMX) the most commonly implicated example [244]. 
Whilst belief in overall sulphonamide cross-reactivity persists [245], recent reviews do not 
support cross-reactivity between antibacterial and non-antibacterial sulphonamides 
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[244,246–249]. There is cross-reactivity between antibiotic sulfonamides, especially 
sulfasalazine and sulfamethoxazole [250]. The non-antibacterial sulphonamides (e.g. 
azetazolamide, forusemide, celecoxib, thiazide diuretics, sumatriptan, sotalol, probenacid) 
do not contain the structural region known to cause the allergic response (i.e., N1 
heterocyclic ring; an N-containing ring attached to the N1 nitrogen of the sulfonamide group 
and arylamine group at the N4 position). Although early reports questioned the potential for 
cross-reactivity between TMP-SMX and darunavir [249,251,252], authors have noted an 
absence of TMP-SMX allergy history in those with darunavir hypersensitivity [253–255]. 
Notably patients with a history of sulfa antimicrobial allergy were not excluded from 
darunavir clinical trials.
The potential for cross-reactivity between dapsone and TMP-SMX is now somewhat 
controversial with most reports occurring in HIV-infected individuals without evidence of 
positive rechallenge. The current estimated rate of cross-reactivity is less than previously 
reported (9–11% vs. 20–45%) [256,257]. In those requiring TMP-SMX therapy with a 
history of non-SCAR adverse drug reaction to antibacterial sulfonamide, we recommend a 
supervised oral rechallenge, rather than drug avoidance [258,259].
Antiretroviral
Cross-reactivity between most antiretroviral classes is likely very low due to the lack of 
structural similarities. However, patients with prior severe hypersensitivity to an NNRTI 
should be monitored if new NNRTI therapy is initiated. Mehta and Maartens reported 
recurrent reactions in 12.6% of patients with reported rash who were switched from 
nevirapine to efavirenz, compared with 50% of patients switched from efavirenz to 
nevirapine [260]. Cross-reactivity is reported to be higher between nevirapine and 
delavirdine which have a similar structure, but delavirdine is not currently used because of 
its difficult dosing, pill burden, drug interactions and lower efficacy compared to 
contemporary NNRTIs [261].
Recommendations for antimicrobial use, in relation to likely cross-reactivity, in patients with 
delayed hypersensitivities to isolate antimicrobials are given in Box 1.
Conclusions
In an era of increasing antimicrobial resistance and use of broad-spectrum antimicrobial 
therapy, ensuring patients are correctly “labelled” in respect to antimicrobial-associated IM-
ADRs is essential. Re-exposure to the implicated antimicrobial, especially in the setting of 
SCAR and AHS is associated with significant morbidity and mortality. The key messages 
from this review are:
1. Antimicrobials are a leading cause of T-cell-mediated ADRs.
2. The antimicrobials primarily associated with T-cell-mediated ADRs 
include glycopeptides, sulphonamides, beta-lactams, antiretrovirals and 
hepatitis C antivirals.
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3. An understanding of drug latency and allergy ‘phenotypes’ can aid drug 
causality assessment.
4. Whilst PT and IDT are specific in the diagnosis of T-cell-mediated ADRs, 
they suffer from drug-specific limitations in sensitivity and when negative 
they can never be used as the sole basis for rechallenge.
5. A knowledge of side chain cross-reactivity aids empirical antibiotic choice 
in the setting of IM-ADRs.
6. The use of ex vivo diagnostics, especially ELISpot are promising new 
approaches to assigning causality in antimicrobial associated T-cell-
mediated ADRs.
a. An understanding of cytokine outputs specific to each 
phenotype will aid the development of these tools in the 
future.
7. Predicting T-cell-mediated ADRs via personalised approaches, including 
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Figure 1. Heading: Schematic of proposed T-cell-mediated ADR pathogenesis theories
(i) The hapten/prohapten model is where an antigen (e.g. antibiotic) covalently binds to a 
self-peptide, is intracellularly processed and then presented with MHC to T cells as a 
‘foreign antigen’ [51,52]. An example of the hapten/prohapten model is when penicillin G 
derivatives bind lysine residues on serum albumin [53–55].
(ii) The p-i concept (the pharmacological interaction with immune receptor) is based upon 
non-covalent binding of antigens to HLA or TCR without immune processing, explaining 
how reactions can occur upon first presentation [51,56].
(iii) The ‘altered self-repertoire model’ is based upon drug models (e.g. abacavir) that 
demonstrated that drugs can occupy positions in the peptide binding groove of the MHC, 
altering the binding cleft and subsequently the specificity of MHC binding [57–59]. Source: 
[51,52], [53–55], [51,56], [57–59].
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